Multiple myeloma exacerbation following utilization of bone morphogenetic protein-2 in lateral lumbar interbody fusion: A case report and review of the literature

Spine Journal

Volumn 14, Issue 4, 2014, Pages

  Hughes, Alexander P ^a   Taher, Fadi ^a   Farshad, Mazda ^a   Aichmair, Alexander ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Bone morphogenetic protein 2; Complication; Lateral lumbar interbody fusion; LLIF; Multiple myeloma; XLIF

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN 2; COMPLEMENT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN KAPPA CHAIN; PARAPROTEIN;

AGED; ARTICLE; BONE BIOPSY; BONE RADIOGRAPHY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; LATERAL LUMBAR INTERBODY FUSION; LIMB WEAKNESS; LOW BACK PAIN; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIPLE MYELOMA; PARESTHESIA; PRIORITY JOURNAL; SCOLIOSIS; SPINE FUSION; SPONDYLOLISTHESIS; TUMOR FLARE; VERY ELDERLY; WALKING DIFFICULTY; ADVERSE EFFECTS; COMPUTER ASSISTED TOMOGRAPHY; LUMBAR VERTEBRA; PROCEDURES; RADIOGRAPHY; SURGERY; TREATMENT OUTCOME;

AGED, 80 AND OVER; BONE MORPHOGENETIC PROTEIN 2; FEMALE; HUMANS; LUMBAR VERTEBRAE; MULTIPLE MYELOMA; SPINAL FUSION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84896963460     PISSN: 15299430     EISSN: 18781632     Source Type: Journal    
DOI: 10.1016/j.spinee.2013.10.020     Document Type: Article

References (34)

1. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988;242:1528-34. (Pubitemid 19023695)
2. Cahill KS, Chi JH, Day A, Claus EB. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 2009;302:58-66.
3. Burkus JK, Gornet MF, Schuler TC, et al. Six-year outcomes of anterior lumbar interbody arthrodesis with use of interbody fusion cages and recombinant human bone morphogenetic protein-2. J Bone Joint Surg Am 2009;91:1181-9.
4. Boden SD, Martin GJ Jr, Horton WC, et al. Laparoscopic anterior spinal arthrodesis with rhBMP-2 in a titanium interbody threaded cage. J Spinal Disord 1998;11:95-101. (Pubitemid 28185906)
5. Hecht BP, Fischgrund JS, Herkowitz HN, et al. The use of recombinant human bone morphogenetic protein 2 (rhBMP-2) to promote spinal fusion in a nonhuman primate anterior interbody fusion model. Spine 1999;24:629-36. (Pubitemid 29162904)
6. Burkus JK, Gornet MF, Dickman CA, Zdeblick TA. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 2002;15:337-49.
7. Glassman SD, Carreon LY, Djurasovic M, et al. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age. Spine 2008;33:2843-9.
8. Boakye M, Mummaneni PV, Garrett M, et al. Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic protein. J Neurosurg Spine 2005;2:521-5.
9. Mroz TE, Wang JC, Hashimoto R, Norvell DC. Complications related to osteobiologics use in spine surgery: a systematic review. Spine 2010;35(9 Suppl):S86-104.
10. Glassman SD, Howard JM, Sweet A, Carreon LY. Complications and concerns with osteobiologics for spine fusion in clinical practice. Spine 2010;35:1621-8.
11. Glassman SD, Howard J, Dimar J, et al. Complications with recombinant human bone morphogenic protein-2 in posterolateral spine fusion: a consecutive series of 1037 cases. Spine 2011;36:1849-54.
12. Wong DA, Kumar A, Jatana S, et al. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 2008;8:1011-8.
13. Rihn JA, Patel R, Makda J, et al. Complications associated with single-level transforaminal lumbar interbody fusion. Spine J 2009;9:623-9.
14. Chen NF, Smith ZA, Stiner E, et al. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion. J Neurosurg Spine 2010;12:40-6.
15. Carragee EJ, Mitsunaga KA, Hurwitz EL, Scuderi GJ. Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study. Spine J 2011;11:511-6.
16. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011;11:471-91.
17. Lykissas MG, Aichmair A, Sama AA, et al. Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a cohort-controlled study. Spine J 2013 Nov 20. Epub ahead of print.
18. Aichmair A, Girardi FP, Hughes AP, Sama AA, et al. Symptomatic heterotopic bone formation after rhBMP-2 utilization in lateral lumbar interbody fusion. Spine J 2013;13:1411-2.
19. Taher F, Lebl DR, Hughes AP, Girardi FP. Contralateral psoas seroma after transpsoas lumbar interbody fusion with bone morphogenetic protein-2 implantation. Spine J 2013;13:e1-5.
20. Mannion RJ, Nowitzke AM, Wood MJ. Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2 - but what is the cost? Spine J 2011;11:527-33.
21. Thawani JP, Wang AC, Than KD, et al. Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery 2010;66:233-46; discussion 246.
22. Fukuda N, Saitoh M, Kobayashi N, Miyazono K. Execution of BMP-4-induced apoptosis by p53-dependent ER dysfunction in myeloma and B-cell hybridoma cells. Oncogene 2006;25:3509-17. (Pubitemid 43901672)
23. Hjertner O, Hjorth-Hansen H, Borset M, et al. Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood 2001;97:516-22. (Pubitemid 32060339)
24. Holien T, Vatsveen TK, Hella H, et al. Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by smad-dependent repression of MYC. Leukemia 2012;26:1073-80.
25. Kawamura C, Kizaki M, Ikeda Y. Bone morphogenetic protein (BMP)-2 induces apoptosis in human myeloma cells. Leuk Lymphoma 2002;43:635-9. (Pubitemid 34232935)
26. Kawamura C, Kizaki M, Yamato K, et al. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood 2000;96:2005-11.
27. Ro TB, Holt RU, Brenne AT, et al. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 2004;23:3024-32. (Pubitemid 38648193)
28. Seckinger A, Meissner T, Moreaux J, et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 2009;28:3866-79.
29. Ozgur BM, Aryan HE, Pimenta L, Taylor WR. Extreme lateral interbody fusion (XLIF): a novel surgical technique for anterior lumbar interbody fusion. Spine J 2006;6:435-43. (Pubitemid 43964530)
30. Food and Drug Administration (FDA). Executive summary for P050036 Medtronic's AMPLIFY™ rhBMP-2 matrix; Orthopaedic and Rehabilitation Devices Advisory Panel. 2010. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/ MedicalDevicesAdvisoryCommittee/OrthopaedicandRehabilitationDevicesPanel/ UCM220079.pdf. Accessed March 19, 2013.
31. Food and Drug Administration (FDA). Summary of safety and effectiveness data for P000058 Medtronic's InFUSE™ Bone Graft/LT-CAGE™ lumbar tapered fusion device; Orthopaedic and Rehabilitation Devices Advisory Panel. 2002. Available at: http://www.accessdata.fda.gov/cdrh-docs/pdf/P000058b.pdf. Accessed April 15, 2013.
32. Kelly MP, Savage JW, Bentzen SM, et al. Cancer risk from recombinant human bone morphogenetic protein-2 exposure in spinal fusion. Paper presented at: 2013 Annual Meeting of the Lumbar Spine Research Society; April 11-12, 2013; Chicago, IL. Available at: http://thejns. org/doi/pdf/10.3171/2013.4.FOC- LSRSabstracts. Accessed April 15, 2013.
33. Devine JG, Dettori JR, France JC, et al. The use of rhBMP in spine surgery: is there a cancer risk? Evid Based Spine Care J 2012;3:35-41.
34. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2009 (Vintage 2009 populations). Updated August 20, 2012. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2009- pops09/. Based on November 2011 SEER data submission, posted to the SEERWeb site, April 2012. Accessed December 3, 2013.